Background
UniProt entry P98082 encodes a protein with potential involvement in cellular pathways relevant to ovarian carcinoma pathogenesis. While the precise functional role of this protein in ovarian cancer remains to be elucidated, its expression patterns suggest it may contribute to tumor biology. Given the complexity and heterogeneity of ovarian carcinoma, identifying novel molecular targets such as P98082 is critical to expanding the repertoire of candidate biomarkers and therapeutic avenues. This protein represents a putative target that warrants further experimental validation in the context of ovarian carcinoma.
Data-mining rationale
The identification of P98082 as a candidate target arose from a systematic cross-referencing of reviewed human UniProt entries annotated for "ovarian carcinoma" against a broad compendium of 686 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). Several datasets profiling ovarian carcinoma samples (GDS:200333343, GDS:200322784, GDS:200301530, GDS:200319500, GDS:200315735) revealed differential expression signals for P98082. These findings highlight its potential relevance in ovarian carcinoma and underscore the utility of integrative bioinformatic approaches to uncover putative targets from existing transcriptomic data.
Why prior analyses may have missed this
Many of the original microarray studies included in this analysis were conducted before the adoption of modern empirical-Bayes statistical frameworks such as the limma package, which provides robust multiple-testing correction using methods like the Benjamini-Hochberg false discovery rate (FDR). As a result, earlier analyses may have lacked the statistical power or rigor to detect subtle but biologically meaningful differential expression of P98082. Furthermore, the absence of any registered Phase 1 or later clinical development programs targeting P98082 suggests that it has not yet been prioritized for translational research, possibly due to limitations in prior data analysis methodologies.
Reasoning for further validation
P98082 emerges as a putative target in ovarian carcinoma based on consistent expression signals across multiple independent transcriptomic datasets. Re-analysis of these GEO datasets using limma with stringent FDR control is necessary to confirm statistically significant differential expression. Subsequent validation by quantitative PCR in independent patient cohorts would provide additional support for its disease association. Examination of tissue specificity through resources such as GTEx and the Human Protein Atlas can clarify its expression profile in normal versus malignant ovarian tissue. Network and pathway analyses using tools like STRING or OmniPath may elucidate its biological context and potential interactions relevant to tumorigenesis. If validated, assessment of druggability via databases such as DGIdb and ChEMBL could inform early-stage therapeutic targeting strategies. Collectively, these steps will help clarify the biological and clinical relevance of P98082 in ovarian carcinoma and guide future translational research efforts.